Manning & Napier Group, LLC Seagen Inc. Transaction History

Manning & Napier Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$117.37 - $139.17 $361,382 - $428,504	-3,079 Reduced 0.85%	359,085 $0
Q3 2022 Oct 18, 2022	BUY	$135.27 - $180.11 $839,079 - $1.12 Million	6,203 Added 1.74%	362,164 $49.6 Million
Q2 2022 Jul 12, 2022	SELL	$108.81 - $179.33 $65.4 Million - $108 Million	-601,491 Reduced 62.82%	355,961 $63 Million
Q1 2022 Apr 19, 2022	BUY	$119.61 - $157.85 $2.72 Million - $3.59 Million	22,759 Added 2.43%	957,452 $138 Million
Q4 2021 Jan 27, 2022	SELL	$142.57 - $190.86 $1.14 Million - $1.52 Million	-7,977 Reduced 0.85%	934,693 $145 Million
Q3 2021 Oct 14, 2021	BUY	$142.45 - $169.82 $1.66 Million - $1.98 Million	11,631 Added 1.25%	942,670 $160 Million
Q2 2021 Jul 19, 2021	BUY	$135.08 - $161.1 $2.34 Million - $2.79 Million	17,342 Added 1.9%	931,039 $147 Million
Q1 2021 Apr 28, 2021	BUY	$137.51 - $190.8 $112 Million - $156 Million	817,452 Added 849.34%	913,697 $127 Million
Q4 2020 Jan 20, 2021	BUY	$164.63 - $211.93 $15.8 Million - $20.4 Million	96,245 New	96,245 $16.9 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Manning & Napier Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Manning & Napier Group, LLC with notifications on news.